Takaku F
Gan To Kagaku Ryoho. 1987 Mar;14(3 Pt 1):645-52.
Recombinant interferon-gamma (rIFN-gamma) was given to patients with malignancies by continuous daily administration or by intermittent high doses. Local administration was performed for patients with skin malignancy, and bladder and hepatic carcinoma. Among 239 cases eligible for evaluation (144 cases treated by systemic administration and 95 cases by local injection), complete response was observed in one case each of renal cell carcinoma, malignant lymphoma and mycosis fungoides, all treated by systemic administration. Intermittent high doses of rIFN-gamma induced a response rate of 21.4% in renal cell carcinoma. This rate was higher than the 8.6% obtained following continuous administration. Average response rate to local injection of rIFN-gamma in skin malignancies was 55.3%. This value was comparable with that obtained by IFN-alpha treatment. Fever was observed in 89% of the cases treated by systemic administration. Chills, malaise and anorexia were the main side effects. Local injection also induced similar side effects, although the incidence was lower in comparison with systemic administration. Incidence of side effects was higher in the intermittent high-dose group than in the continuous administration group for all items except fever. However, patients showed good tolerance to high doses of rIFN-gamma reaching 40 X 10(6) U/m2/day.
重组干扰素-γ（rIFN-γ）通过每日持续给药或间歇性大剂量给药的方式给予恶性肿瘤患者。对皮肤恶性肿瘤、膀胱癌和肝癌患者进行局部给药。在239例符合评估条件的病例中（144例接受全身给药治疗，95例接受局部注射治疗），肾细胞癌、恶性淋巴瘤和蕈样肉芽肿各有1例经全身给药治疗后出现完全缓解。间歇性大剂量rIFN-γ治疗肾细胞癌的缓解率为21.4%。该缓解率高于持续给药后的8.6%。皮肤恶性肿瘤局部注射rIFN-γ的平均缓解率为55.3%。该数值与干扰素-α治疗获得的数值相当。全身给药治疗的病例中89%出现发热。寒战、不适和厌食是主要的副作用。局部注射也会引发类似的副作用，尽管与全身给药相比发生率较低。除发热外，间歇性大剂量组所有项目的副作用发生率均高于持续给药组。然而，患者对高达40×10(6)U/m2/天的大剂量rIFN-γ耐受性良好。
